Skip to content

Research on Brain Function in Patients with Vascular Cognitive Impairment Treated by Transcutaneous Auricular Vagus Nerve Stimulation at Different Frequencies

Research on Brain Function in Patients with Vascular Cognitive Impairment Treated by Transcutaneous Auricular Vagus Nerve Stimulation at Different Frequencies

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129404
Enrollment
Unknown
Registered
2026-08-04
Start date
2024-12-30
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Cognitive Impairment

Interventions

1Hz-taVNS:Patients remained seated and received transcutaneous vagus nerve stimulation (tVNS) concurrently with routine one-on-one computer-assisted cognitive training. After degreasing the left conch
25Hz-taVNS:Patients remained seated and received transcutaneous vagus nerve stimulation (tVNS) concurrently with routine one-on-one computer-assisted cognitive training. After degreasing the left conc

Sponsors

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for Vascular Cognitive Impairment (VCI); 2. Have a Clinical Dementia Rating (CDR) classification of Mild or Moderate, with a total score = 7 on the Hachinski Ischemic Scale (HIS); 6. Score <= 17 on the Hamilton Depression Scale (HAMD); 7. Voluntarily agree to participate in this clinical observational study and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Dementia attributed to other etiologies, including but not limited to brain tumor, other neurodegenerative diseases (e.g., Alzheimer's disease), demyelinating disorders, major systemic medical conditions, or metabolic abnormalities; 2. Presence of severe neurological deficits (e.g., aphasia, severe visual or auditory impairment) that would preclude adequate cooperation with study assessments; 3. History of severe substance abuse, including alcohol dependence, illicit drug use, or misuse of psychoactive medications; 4. Concurrent severe cardiac, hepatic, renal, or other major organ system diseases, or clinically unstable medical conditions; 5. Current participation or participation within the past two weeks in another clinical trial involving cognitive interventions or assessments; 6. Current use of medications specifically intended to enhance or improve cognitive function.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment-Basic Chinese Version ,MoCA-B;EEG parameters;

Secondary

MeasureTime frame
Mini-mental state examination,MMSE;the Hopkins Verbal Learning Test-Revised,HVLT-R;Boston Naming Test,BNT;Clock Drawing Test, CDT4;functional activities questionnaire,FAQ;Tail making teat,TMT;

Countries

CHINA

Contacts

Public ContactWang Ran

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

2389364248@qq.com+86 155 6290 9238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026